Toripalimab and BCG for high-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have high-risk or very high-risk non-muscle-invasive bladder cancer (NMIBC) that hasn't spread into the muscle layer of your bladder.
- You have not received BCG therapy or immune checkpoint inhibitors before.
- You are in good physical condition (fully active or able to do light work) and your blood counts, liver, and kidney function are adequate.
- You are not pregnant and are willing to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medications—one that targets HER2 on cancer cells and one that boosts your immune system—given directly into the bladder. It is for people with high-risk bladder cancer that hasn't spread into the muscle, and who haven't had BCG therapy or for whom BCG didn't work.
This study tests a newer way to remove bladder tumors (called ERBT) combined with BCG, a standard immunotherapy placed in the bladder, for people with bladder cancer that is not too advanced. The goal is to see if this combination helps reduce the chance of the cancer coming back.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests whether radiation therapy (high-energy beams to kill cancer cells) can be a good treatment for bladder cancer that hasn't gone away after BCG therapy, offering an alternative to surgery to remove the bladder. It aims to see if this approach can control the cancer while possibly preserving your bladder.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.